Bevacizumab biosimilar - BIOCND

Drug Profile

Bevacizumab biosimilar - BIOCND

Alternative Names: BCD 500

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BIOCND
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cancer

Most Recent Events

  • 26 Jul 2017 Phase-III clinical trials in Cancer in South Korea (Parenteral) (BIOCND pipeline, July 2017)
  • 16 Dec 2016 Preclinical trials in Cancer in South Korea (Parenteral), before December 2016
  • 16 Dec 2016 BIOCND files an IND application in South Korea for Cancer, before December 2016 (BIOCND pipeline, December 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top